If you would like to give to a specific research program or support the work of a particular researcher, contact our fundraising team today.
The innovative test is a fingerprick sample that is collected in the home and mailed to the lab.
The study, led by WEHI clinician scientist and Royal Melbourne Hospital (RMH) endocrinologist Associate Professor John Wentworth, looked at over 17,000 children and young adults who were screened for type 1 diabetes using a regular blood test.
World-first study finds blood test for early diagnosis of type 1 diabetes can prevent serious illness and hospitalisation in children.
The innovative test can be done at the home and mailed to a lab.
Type 1 diabetes is an autoimmune condition where the immune system is activated to destroy the cells in the pancreas which produce insulin.
Without insulin, the body’s cells cannot turn glucose (sugar) into energy, meaning people with type 1 diabetes depend on insulin every day of their lives to compensate for what their bodies cannot naturally produce.
Associate Professor John Wentworth, a clinician scientist in WEHI’s Population Health and Immunity division, said: “The in-home fingerprick test allows us to get a result back to families sooner, which will allow us to start treatment before kids get really sick.
“Type 1 diabetes can be very difficult to identify in children so early diagnosis is really important.
“The fingerprick test will allow us to start treatment before kids get really sick and will give us time to ensure families have enough time to learn how to manage type 1 diabetes, and the complexity of diet and insulin therapy.”
While the exact cause of type 1 diabetes is unknown, the condition is believed to have a strong family link and cannot be prevented.
The study primarily focused on families with a history of Type 1 diabetes, due to the risk of disease being 15 times greater than the general population. However, only one in 10 newly diagnosed children have a family history of type 1 diabetes, meaning screening the entire population will be essential.
“The aim of this study is to be able to diagnose type 1 diabetes early in as many children as we can,” said Associate Professor Wentworth.
“Early diagnosis prevents serious illness and affords opportunities to use immunotherapy to delay progression to insulin injections.”
The team of researchers are the first to use the blood spot assay to screen diabetes in Australia, and the RMH is the first in the world to prove that blood samples collected in the home is a suitable way to prevent type 1 diabetes.
“We want to make type 1 diabetes screening accessible to every Australian child no matter where they live. Our recent work has proven that we can do this cheaply, accurately, and conveniently,” Associate Professor Wentworth said.
This work was made possible with support from Diabetes Australia, Lions Australia Diabetes Foundation, the Australian National Health and Medical Research Council and the Victorian Government.
The study “Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand” is published in Pediatric Diabetes (DOI: 10.1111/pedi.13422).
WEHI authors: John Wentworth, Leonard Harrison
Media enquiries